{
  "url": "https://finance.yahoo.com/news/asian-markets-estimated-value-stocks-044442261.html",
  "authorsByline": "Simply Wall St",
  "articleId": "42f41a72a9574311bd3b75447a4bfd01",
  "source": {
    "domain": "finance.yahoo.com",
    "location": {
      "country": "us",
      "state": "CA",
      "county": "Santa Clara County",
      "city": "Sunnyvale",
      "coordinates": {
        "lat": 37.3688301,
        "lon": -122.036349
      }
    }
  },
  "imageUrl": "https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316",
  "country": "us",
  "language": "en",
  "pubDate": "2025-08-25T04:44:42+00:00",
  "addDate": "2025-08-25T05:07:23.753411+00:00",
  "refreshDate": "2025-08-25T05:07:23.753412+00:00",
  "score": 1.0,
  "title": "Asian Market's Estimated Value Stocks For August 2025",
  "description": "As the Asian markets navigate a landscape influenced by global economic shifts, including potential rate cuts and evolving trade dynamics, investors are keenly observing opportunities for value investments. In this context, identifying stocks that are perceived as undervalued can be particularly appealing, offering potential for growth amid broader market fluctuations.",
  "content": "As the Asian markets navigate a landscape influenced by global economic shifts, including potential rate cuts and evolving trade dynamics, investors are keenly observing opportunities for value investments. In this context, identifying stocks that are perceived as undervalued can be particularly appealing, offering potential for growth amid broader market fluctuations.\n\nClick here to see the full list of 269 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.\n\nUnderneath we present a selection of stocks filtered out by our screen.\n\nOverview: Simcere Pharmaceutical Group Limited is an investment holding company that focuses on the research, development, manufacture, and sale of pharmaceutical products within China, with a market cap of approximately HK$34.89 billion.\n\nOperations: The company generates revenue from its pharmaceuticals segment, amounting to CN\u00a57.11 billion.\n\nSimcere Pharmaceutical Group, trading at HK$14.1, is significantly undervalued compared to its fair value estimate of HK$19.08. Recent earnings show a solid performance with sales rising to CNY 3.58 billion and net income increasing to CNY 603.61 million for the first half of 2025, reflecting strong cash flow potential. The company's strategic collaborations and new drug approvals could further enhance revenue streams, supporting forecasts of significant earnings growth over the next three years.\n\u2022 Insights from our recent growth report point to a promising forecast for Simcere Pharmaceutical Group's business outlook.\n\u2022 Unlock comprehensive insights into our analysis of Simcere Pharmaceutical Group stock in this financial health report.\n\nOverview: Chugai Pharmaceutical Co., Ltd. is involved in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals both in Japan and internationally with a market cap of \u00a510.32 trillion.\n\nOperations: Chugai Pharmaceutical Co., Ltd. generates revenue through its involvement in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals across Japan and international markets.",
  "medium": "Article",
  "links": [
    "https://simplywall.st/company/id/6fb23837-8aa9-4491-ae86-533b66bc5506/valuation?utm_medium=finance_user&amp;utm_campaign=infographic&amp;utm_source=yahoo&amp;blueprint=4014157",
    "https://simplywall.st/company/id/664ac572-b488-49cf-99f5-750a89324d62?utm_medium=finance_user&utm_campaign=cta&utm_source=yahoo&blueprint=4014157",
    "https://simplywall.st/discover/investing-ideas/168/undervalued-stocks-based-on-cash-flows/global?utm_medium=finance_user&utm_campaign=conclusion-grid&utm_source=yahoo&blueprint=4014157",
    "https://simplywall.st/company/id/6fb23837-8aa9-4491-ae86-533b66bc5506/future?utm_medium=finance_user&utm_campaign=integrated-pitch&utm_source=yahoo&blueprint=4014157",
    "https://simplywall.st/company/id/6fb23837-8aa9-4491-ae86-533b66bc5506/health?utm_medium=finance_user&utm_campaign=integrated-pitch&utm_source=yahoo&blueprint=4014157",
    "https://simplywall.st/company/id/6fb23837-8aa9-4491-ae86-533b66bc5506?utm_medium=finance_user&utm_campaign=cta&utm_source=yahoo&blueprint=4014157"
  ],
  "labels": [
    {
      "name": "Roundup"
    }
  ],
  "claim": "",
  "verdict": "",
  "keywords": [
    {
      "name": "Simcere Pharmaceutical Group stock",
      "weight": 0.12145378
    },
    {
      "name": "Simcere Pharmaceutical Group",
      "weight": 0.10842299
    },
    {
      "name": "Simcere Pharmaceutical Group Limited",
      "weight": 0.10502059
    },
    {
      "name": "Chugai Pharmaceutical Co.",
      "weight": 0.08685629
    },
    {
      "name": "stocks",
      "weight": 0.085874386
    },
    {
      "name": "significant earnings growth",
      "weight": 0.08142603
    },
    {
      "name": "value investments",
      "weight": 0.074308224
    },
    {
      "name": "broader market fluctuations",
      "weight": 0.07418818
    },
    {
      "name": "international markets",
      "weight": 0.072227105
    },
    {
      "name": "sale",
      "weight": 0.07164576
    }
  ],
  "topics": [
    {
      "name": "Asian"
    },
    {
      "name": "Markets"
    }
  ],
  "categories": [
    {
      "name": "Finance"
    }
  ],
  "taxonomies": [
    {
      "name": "/News/Business News/Financial Markets News",
      "score": 0.9931640625
    },
    {
      "name": "/Finance/Investing/Stocks & Bonds",
      "score": 0.96533203125
    },
    {
      "name": "/News/Business News/Company News",
      "score": 0.9052734375
    },
    {
      "name": "/Business & Industrial/Pharmaceuticals & Biotech",
      "score": 0.57373046875
    }
  ],
  "sentiment": {
    "positive": 0.57818025,
    "negative": 0.032128677,
    "neutral": 0.3896911
  },
  "summary": "The list of 269 stocks from our Undervalued Asian Stocks Based On Cash Flows screener includes Simcere Pharmaceutical Group Limited, an investment holding company that focuses on the research, development, manufacture, and sale of pharmaceutical products in China. The company, which generates revenue from its pharmaceuticals segment, is trading at HK$14.1 and is significantly undervalued compared to its fair value estimate of HK$19.08. Recent earnings show a strong performance, with sales rising to CNY 3.58 billion and net income increasing to CNO 603.61 million for the first half of 2025.",
  "shortSummary": "The Undervalued Asian Stock Market index reveals 269 undervalued stocks, including Simcere Pharmaceutical Group, with strong earnings prospects and potential for growth amid global economic shifts.",
  "translation": "",
  "translatedTitle": "",
  "translatedDescription": "",
  "translatedSummary": "",
  "reprint": true,
  "reprintGroupId": "0802ea7e55f74f719b4d5471c1ad0873",
  "places": [],
  "scraped_sources": [
    {
      "url": "https://simplywall.st/company/id/6fb23837-8aa9-4491-ae86-533b66bc5506/valuation?utm_medium=finance_user&amp;utm_campaign=infographic&amp;utm_source=yahoo&amp;blueprint=4014157",
      "text": "Is 2096 undervalued compared to its fair value, analyst forecasts and its price relative to the market?\nValuation Score\n2/6\nValuation Score 2/6\nBelow Fair Value\nSignificantly Below Fair Value\nPrice-To-Earnings vs Peers\nPrice-To-Earnings vs Industry\nPrice-To-Earnings vs Fair Ratio\nAnalyst Forecast\nShare Price vs Fair Value\nWhat is the Fair Price of 2096 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.\nDiscounted Cash Flow\nSimply Wall St\nHK$19.08\nFair Value\n26.1% undervalued intrinsic discount\n5\nNumber of Analysts\nBelow Fair Value: 2096 (HK$14.1) is trading below our estimate of fair value (HK$19.08)\nSignificantly Below Fair Value: 2096 is trading below fair value by more than 20%.\nKey Valuation Metric\nWhich metric is best to use when looking at relative valuation for 2096?\nKey metric: As 2096 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.\nThe above table shows the Price to Earnings ratio for 2096. This is calculated by dividing 2096's market cap by their current\nearnings.\nWhat is 2096's PE Ratio?\nPE Ratio\n36.3x\nEarnings\nCN\u00a5880.17m\nMarket Cap\nCN\u00a531.99b\n2096 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.\nPrice-To-Earnings vs Industry: 2096 is expensive based on its Price-To-Earnings Ratio (36.3x) compared to the Hong Kong Pharmaceuticals industry average (12.2x).\nPrice to Earnings Ratio vs Fair Ratio\nWhat is 2096's PE Ratio\ncompared to its\nFair PE Ratio?\nThis is the expected PE Ratio taking into\naccount the company's forecast earnings growth, profit margins\nand other risk factors.\n2096 PE Ratio vs Fair Ratio.\nFair Ratio\nCurrent PE Ratio\n36.3x\nFair PE Ratio\n26.2x\nPrice-To-Earnings vs Fair Ratio: 2096 is expensive based on its Price-To-Earnings Ratio (36.3x) compared to the estimated Fair Price-To-Earnings Ratio (26.2x).\nAnalyst Price Targets\nWhat is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?\nThe above table shows the analyst 2096 forecast and predictions for the stock price in 12 month\u2019s time.\nDate\nShare Price\nAverage 1Y Price Target\nDispersion\nHigh\nLow\n1Y Actual price\nAnalysts\nCurrent\nHK$14.10\nHK$15.76\n+11.75%\n15.30%\nHK$19.20\nHK$12.27\nn/a\n5\nAug \u201926\nHK$12.50\nHK$13.58\n+8.65%\n6.84%\nHK$14.57\nHK$12.25\nn/a\n5\nJul \u201926\nHK$11.12\nHK$12.25\n+10.16%\n17.06%\nHK$14.66\nHK$9.09\nn/a\n5\nJun \u201926\nHK$12.84\nHK$9.88\n-23.09%\n7.58%\nHK$10.71\nHK$8.95\nn/a\n5\nMay \u201926\nHK$8.76\nHK$9.81\n+11.94%\n6.37%\nHK$10.49\nHK$8.76\nn/a\n5\nApr \u201926\nHK$8.25\nHK$9.63\n+16.69%\n7.89%\nHK$10.52\nHK$8.74\nn/a\n5\nMar \u201926\nHK$7.93\nHK$8.99\n+13.33%\n12.65%\nHK$10.65\nHK$7.20\nn/a\n5\nFeb \u201926\nHK$6.85\nHK$8.99\n+31.19%\n12.65%\nHK$10.65\nHK$7.20\nn/a\n5\nJan \u201926\nHK$7.10\nHK$8.97\n+26.32%\n12.85%\nHK$10.69\nHK$7.23\nn/a\n5\nDec \u201925\nHK$7.00\nHK$8.52\n+21.71%\n9.68%\nHK$9.86\nHK$7.40\nn/a\n6\nNov \u201925\nHK$6.95\nHK$8.52\n+22.58%\n9.68%\nHK$9.86\nHK$7.40\nn/a\n6\nOct \u201925\nHK$6.84\nHK$8.36\n+22.27%\n10.39%\nHK$9.90\nHK$7.43\nn/a\n6\nSep \u201925\nHK$5.91\nHK$8.39\n+41.99%\n11.15%\nHK$10.11\nHK$7.42\nn/a\n6\nAug \u201925\nHK$5.29\nHK$8.60\n+62.64%\n8.72%\nHK$9.94\nHK$7.62\nHK$12.50\n6\nJul \u201925\nHK$5.73\nHK$8.64\n+50.71%\n8.61%\nHK$10.00\nHK$7.67\nHK$11.12\n7\nJun \u201925\nHK$5.86\nHK$8.64\n+47.36%\n8.61%\nHK$10.00\nHK$7.67\nHK$12.84\n7\nMay \u201925\nHK$5.40\nHK$8.64\n+59.92%\n8.61%\nHK$10.00\nHK$7.67\nHK$8.76\n7\nApr \u201925\nHK$5.31\nHK$8.41\n+58.29%\n6.32%\nHK$9.20\nHK$7.67\nHK$8.25\n6\nMar \u201925\nHK$5.50\nHK$10.36\n+88.37%\n14.33%\nHK$13.09\nHK$8.11\nHK$7.93\n7\nFeb \u201925\nHK$5.25\nHK$10.57\n+101.37%\n14.30%\nHK$13.17\nHK$8.16\nHK$6.85\n7\nJan \u201925\nHK$6.73\nHK$10.76\n+59.93%\n13.30%\nHK$13.15\nHK$8.14\nHK$7.10\n7\nDec \u201924\nHK$7.33\nHK$10.64\n+45.12%\n12.94%\nHK$12.97\nHK$8.17\nHK$7.00\n7\nNov \u201924\nHK$6.87\nHK$10.63\n+54.66%\n13.08%\nHK$12.89\nHK$8.12\nHK$6.95\n7\nOct \u201924\nHK$6.40\nHK$10.62\n+65.96%\n14.13%\nHK$12.88\nHK$8.11\nHK$6.84\n6\nSep \u201924\nHK$6.11\nHK$10.67\n+74.68%\n14.10%\nHK$12.97\nHK$8.17\nHK$5.91\n6\nAug \u201924\nHK$7.51\nHK$13.58\n+80.80%\n19.18%\nHK$18.96\nHK$11.44\nHK$5.29\n6\nAnalystConsensusTarget\nConsensus Narrative from 5 Analysts\nHK$15.76\nFair Value\n10.5% undervalued intrinsic discount\n5\nNumber of Analysts\nAnalyst Forecast: Target price is less than 20% higher than the current share price.\nDiscover undervalued companies\n7D\n1Y\n7D\n1Y\n7D\n1Y\nCompany Analysis and Financial Data Status\nData\nLast Updated (UTC time)\nCompany Analysis\n2025/08/24 05:49\nEnd of Day Share Price\n2025/08/22 00:00\nEarnings\n2025/06/30\nAnnual Earnings\n2024/12/31\nData Sources\nThe data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.\n* Example for US securities, for non-US equivalent regulatory forms and sources are used.\nUnless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.\nAnalysis Model and Snowflake\nDetails of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.\nLearn about the world class team who designed and built the Simply Wall St analysis model.\nIndustry and Sector Metrics\nOur industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.\nAnalyst Sources\nSimcere Pharmaceutical Group Limited is covered by 17 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day."
    },
    {
      "url": "https://simplywall.st/company/id/6fb23837-8aa9-4491-ae86-533b66bc5506/future?utm_medium=finance_user&utm_campaign=integrated-pitch&utm_source=yahoo&blueprint=4014157",
      "text": "Simcere Pharmaceutical Group Future Growth\nFuture criteria checks 4/6\nSimcere Pharmaceutical Group is forecast to grow earnings and revenue by 24.4% and 14.2% per annum respectively. EPS is expected to grow by 24.3% per annum. Return on equity is forecast to be 18.8% in 3 years.\nKey information\n24.4%\nEarnings growth rate\n24.26%\nEPS growth rate\n| Pharmaceuticals earnings growth | 12.9% |\n| Revenue growth rate | 14.2% |\n| Future return on equity | 18.77% |\n| Analyst coverage | Low |\n| Last updated | 23 Aug 2025 |\nRecent future growth updates\nRecent updates\nSimcere Pharmaceutical Group Limited's (HKG:2096) 30% Jump Shows Its Popularity With Investors\nJul 29Simcere Pharmaceutical Group Limited (HKG:2096) Looks Just Right With A 28% Price Jump\nMay 20We Like Simcere Pharmaceutical Group's (HKG:2096) Earnings For More Than Just Statutory Profit\nMay 06Simcere Pharmaceutical Group Limited's (HKG:2096) Price In Tune With Revenues\nMar 06Simcere Pharmaceutical Group Limited's (HKG:2096) P/S Still Appears To Be Reasonable\nNov 21Simcere Pharmaceutical Group Limited (HKG:2096) Not Lagging Market On Growth Or Pricing\nJul 29Why Simcere Pharmaceutical Group's (HKG:2096) Shaky Earnings Are Just The Beginning Of Its Problems\nMay 01Simcere Pharmaceutical Group Limited's (HKG:2096) Business And Shares Still Trailing The Market\nDec 29Need To Know: Analysts Just Made A Substantial Cut To Their Simcere Pharmaceutical Group Limited (HKG:2096) Estimates\nAug 28Are Investors Undervaluing Simcere Pharmaceutical Group Limited (HKG:2096) By 40%?\nJun 03Analysts Just Shaved Their Simcere Pharmaceutical Group Limited (HKG:2096) Forecasts Dramatically\nApr 06Estimating The Intrinsic Value Of Simcere Pharmaceutical Group Limited (HKG:2096)\nJan 10Earnings and Revenue Growth Forecasts\n| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |\n|---|---|---|---|---|---|\n| 12/31/2027 | 9,999 | 1,721 | 910 | N/A | 4 |\n| 12/31/2026 | 9,240 | 1,507 | 644 | N/A | 5 |\n| 12/31/2025 | 7,704 | 1,223 | 197 | N/A | 5 |\n| 6/30/2025 | 7,107 | 880 | N/A | N/A | N/A |\n| 3/31/2025 | 6,871 | 807 | N/A | N/A | N/A |\n| 12/31/2024 | 6,635 | 733 | 629 | 1,391 | N/A |\n| 9/30/2024 | 6,487 | -185 | 434 | 1,243 | N/A |\n| 6/30/2024 | 6,340 | -1,102 | 240 | 1,096 | N/A |\n| 3/31/2024 | 6,474 | -194 | -294 | 623 | N/A |\n| 12/31/2023 | 6,608 | 715 | -829 | 151 | N/A |\n| 9/30/2023 | 6,807 | 1,928 | -504 | 369 | N/A |\n| 6/30/2023 | 7,006 | 3,141 | -179 | 587 | N/A |\n| 3/31/2023 | 6,665 | 2,036 | 249 | 971 | N/A |\n| 12/31/2022 | 6,324 | 931 | 676 | 1,354 | N/A |\n| 9/30/2022 | 5,952 | 972 | 673 | 1,180 | N/A |\n| 6/30/2022 | 5,579 | 1,013 | 671 | 1,006 | N/A |\n| 3/31/2022 | 5,290 | 1,260 | 130 | 402 | N/A |\n| 12/31/2021 | 5,000 | 1,507 | -411 | -202 | N/A |\n| 9/30/2021 | 4,852 | 1,274 | -481 | -200 | N/A |\n| 6/30/2021 | 4,703 | 1,042 | -551 | -198 | N/A |\n| 3/31/2021 | 4,606 | 856 | -404 | -51 | N/A |\n| 12/31/2020 | 4,509 | 670 | -256 | 97 | N/A |\n| 9/30/2020 | 4,528 | 699 | -314 | -6 | N/A |\n| 6/30/2020 | 4,548 | 728 | -371 | -109 | N/A |\n| 3/31/2020 | 4,792 | 866 | -53 | 332 | N/A |\n| 12/31/2019 | 5,037 | 1,004 | 265 | 773 | N/A |\n| 12/31/2018 | 4,514 | 734 | N/A | 776 | N/A |\n| 12/31/2017 | 3,868 | 350 | N/A | 939 | N/A |\nAnalyst Future Growth Forecasts\nEarnings vs Savings Rate: 2096's forecast earnings growth (24.4% per year) is above the savings rate (2.7%).\nEarnings vs Market: 2096's earnings (24.4% per year) are forecast to grow faster than the Hong Kong market (11.5% per year).\nHigh Growth Earnings: 2096's earnings are expected to grow significantly over the next 3 years.\nRevenue vs Market: 2096's revenue (14.2% per year) is forecast to grow faster than the Hong Kong market (8.3% per year).\nHigh Growth Revenue: 2096's revenue (14.2% per year) is forecast to grow slower than 20% per year.\nEarnings per Share Growth Forecasts\nFuture Return on Equity\nFuture ROE: 2096's Return on Equity is forecast to be low in 3 years time (18.8%).\nDiscover growth companies\nCompany Analysis and Financial Data Status\n| Data | Last Updated (UTC time) |\n|---|---|\n| Company Analysis | 2025/08/24 05:49 |\n| End of Day Share Price | 2025/08/22 00:00 |\n| Earnings | 2025/06/30 |\n| Annual Earnings | 2024/12/31 |\nData Sources\nThe data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.\n| Package | Data | Timeframe | Example US Source * |\n|---|---|---|---|\n| Company Financials | 10 years |\n| |\n| Analyst Consensus Estimates | +3 years |\n|\n|\n| Market Prices | 30 years |\n| |\n| Ownership | 10 years |\n| |\n| Management | 10 years |\n| |\n| Key Developments | 10 years |\n|\n* Example for US securities, for non-US equivalent regulatory forms and sources are used.\nUnless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.\nAnalysis Model and Snowflake\nDetails of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.\nLearn about the world class team who designed and built the Simply Wall St analysis model.\nIndustry and Sector Metrics\nOur industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.\nAnalyst Sources\nSimcere Pharmaceutical Group Limited is covered by 17 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.\n| Analyst | Institution |\n|---|---|\n| Shaojing Tong | BofA Global Research |\n| Bo Yu | China International Capital Corporation Limited |\n| Shitong Han | Citic Securities Co., Ltd. |"
    },
    {
      "url": "https://simplywall.st/company/id/6fb23837-8aa9-4491-ae86-533b66bc5506?utm_medium=finance_user&utm_campaign=cta&utm_source=yahoo&blueprint=4014157",
      "text": "Simcere Pharmaceutical Group (2096) Stock Overview\nAn investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. More details\n| Snowflake Score | |\n|---|---|\n| Valuation | 2/6 |\n| Future Growth | 4/6 |\n| Past Performance | 2/6 |\n| Financial Health | 6/6 |\n| Dividends | 2/6 |\nRewards\nRisk Analysis\nNo risks detected for 2096 from our risk checks.\n2096 Community Fair Values\nCreate NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.\nSimcere Pharmaceutical Group Limited Competitors\nPrice History & Performance\n| Historical stock prices | |\n|---|---|\n| Current Share Price | HK$14.10 |\n| 52 Week High | HK$14.28 |\n| 52 Week Low | HK$5.27 |\n| Beta | 0.52 |\n| 1 Month Change | 14.26% |\n| 3 Month Change | 38.78% |\n| 1 Year Change | 167.05% |\n| 3 Year Change | 74.94% |\n| 5 Year Change | n/a |\n| Change since IPO | 28.42% |\nRecent News & Updates\nSimcere Pharmaceutical Group Limited's (HKG:2096) 30% Jump Shows Its Popularity With Investors\nJul 29Recent updates\nSimcere Pharmaceutical Group Limited's (HKG:2096) 30% Jump Shows Its Popularity With Investors\nJul 29Simcere Pharmaceutical Group Limited (HKG:2096) Looks Just Right With A 28% Price Jump\nMay 20We Like Simcere Pharmaceutical Group's (HKG:2096) Earnings For More Than Just Statutory Profit\nMay 06Simcere Pharmaceutical Group Limited's (HKG:2096) Price In Tune With Revenues\nMar 06Simcere Pharmaceutical Group Limited's (HKG:2096) P/S Still Appears To Be Reasonable\nNov 21Simcere Pharmaceutical Group Limited (HKG:2096) Not Lagging Market On Growth Or Pricing\nJul 29Why Simcere Pharmaceutical Group's (HKG:2096) Shaky Earnings Are Just The Beginning Of Its Problems\nMay 01Simcere Pharmaceutical Group Limited's (HKG:2096) Business And Shares Still Trailing The Market\nDec 29Need To Know: Analysts Just Made A Substantial Cut To Their Simcere Pharmaceutical Group Limited (HKG:2096) Estimates\nAug 28Are Investors Undervaluing Simcere Pharmaceutical Group Limited (HKG:2096) By 40%?\nJun 03Analysts Just Shaved Their Simcere Pharmaceutical Group Limited (HKG:2096) Forecasts Dramatically\nApr 06Estimating The Intrinsic Value Of Simcere Pharmaceutical Group Limited (HKG:2096)\nJan 10Shareholder Returns\n| 2096 | HK Pharmaceuticals | HK Market | |\n|---|---|---|---|\n| 7D | 13.3% | 0.2% | 0.5% |\n| 1Y | 167.0% | 90.2% | 43.4% |\nReturn vs Industry: 2096 exceeded the Hong Kong Pharmaceuticals industry which returned 90.2% over the past year.\nReturn vs Market: 2096 exceeded the Hong Kong Market which returned 43.4% over the past year.\nPrice Volatility\n| 2096 volatility | |\n|---|---|\n| 2096 Average Weekly Movement | 9.4% |\n| Pharmaceuticals Industry Average Movement | 6.4% |\n| Market Average Movement | 7.1% |\n| 10% most volatile stocks in HK Market | 15.7% |\n| 10% least volatile stocks in HK Market | 3.5% |\nStable Share Price: 2096 has not had significant price volatility in the past 3 months compared to the Hong Kong market.\nVolatility Over Time: 2096's weekly volatility (9%) has been stable over the past year.\nAbout the Company\n| Founded | Employees | CEO | Website |\n|---|---|---|---|\n| 1995 | 6,815 | Jinsheng Ren | www.simcere.com |\nSimcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. The company focuses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; COSELA, a trilaciclib hydrochloride for injection; Iremod, an iguratimod tablet; and XIANNUOXIN simnotrelvir tablets and ritonavir tablets.\nSimcere Pharmaceutical Group Limited Fundamentals Summary\n| 2096 fundamental statistics | |\n|---|---|\n| Market cap | HK$34.89b |\n| Earnings (TTM) | HK$960.09m |\n| Revenue (TTM) | HK$7.75b |\nIs 2096 overvalued?\nSee Fair Value and valuation analysisEarnings & Revenue\n| 2096 income statement (TTM) | |\n|---|---|\n| Revenue | CN\u00a57.11b |\n| Cost of Revenue | CN\u00a51.35b |\n| Gross Profit | CN\u00a55.76b |\n| Other Expenses | CN\u00a54.88b |\n| Earnings | CN\u00a5880.17m |\nLast Reported Earnings\nJun 30, 2025\nNext Earnings Date\nn/a\n| Earnings per share (EPS) | 0.36 |\n| Gross Margin | 81.00% |\n| Net Profit Margin | 12.39% |\n| Debt/Equity Ratio | 14.6% |\nHow did 2096 perform over the long term?\nSee historical performance and comparisonDividends\nCompany Analysis and Financial Data Status\n| Data | Last Updated (UTC time) |\n|---|---|\n| Company Analysis | 2025/08/24 05:49 |\n| End of Day Share Price | 2025/08/22 00:00 |\n| Earnings | 2025/06/30 |\n| Annual Earnings | 2024/12/31 |\nData Sources\nThe data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.\n| Package | Data | Timeframe | Example US Source * |\n|---|---|---|---|\n| Company Financials | 10 years |\n| |\n| Analyst Consensus Estimates | +3 years |\n|\n|\n| Market Prices | 30 years |\n| |\n| Ownership | 10 years |\n| |\n| Management | 10 years |\n| |\n| Key Developments | 10 years |\n|\n* Example for US securities, for non-US equivalent regulatory forms and sources are used.\nUnless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.\nAnalysis Model and Snowflake\nDetails of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.\nLearn about the world class team who designed and built the Simply Wall St analysis model.\nIndustry and Sector Metrics\nOur industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.\nAnalyst Sources\nSimcere Pharmaceutical Group Limited is covered by 17 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.\n| Analyst | Institution |\n|---|---|\n| Shaojing Tong | BofA Global Research |\n| Bo Yu | China International Capital Corporation Limited |\n| Shitong Han | Citic Securities Co., Ltd. |"
    },
    {
      "url": "https://simplywall.st/discover/investing-ideas/168/undervalued-stocks-based-on-cash-flows/global?utm_medium=finance_user&utm_campaign=conclusion-grid&utm_source=yahoo&blueprint=4014157",
      "text": "Results\n860\nCompanies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.\n860 companies\nAmbipar Participa\u00e7\u00f5es e Empreendimentos\nMarket Cap: R$22.3b\nAmbipar Participa\u00e7\u00f5es e Empreendimentos S.A.\nAMBP3\nR$13.40\n7D\n-4.4%\n1Y\n51.9%\nKolmar Korea\nMarket Cap: \u20a91.9t\nResearches, develops, produces, and sells beauty and health products in South Korea and internationally.\nA161890\n\u20a979,100.00\n7D\n-0.8%\n1Y\n12.8%\nWELL Health Technologies\nMarket Cap: CA$1.2b\nOperates as a practitioner-focused digital healthcare company in Canada, the United States, and internationally.\nWELL\nCA$4.92\n7D\n-1.6%\n1Y\n6.5%\nBloomberry Resorts\nMarket Cap: \u20b141.0b\nThrough its subsidiaries, develops, owns, and operates hotels, casinos, and integrated resorts in the Philippines and Korea.\nBLOOM\n\u20b13.57\n7D\n-0.8%\n1Y\n-53.6%\nS Chand\nMarket Cap: \u20b97.0b\nS Chand and Company Limited, an education content company, develops and delivers content, solutions, and services for the early learning, K-12, and higher education segments in India.\nSCHAND\n\u20b9197.85\n7D\n1.9%\n1Y\n-14.2%\nWanguo Gold Group\nMarket Cap: HK$32.0b\nAn investment holding company, engages in mining, ore processing, and sale of concentrate products in the People\u2019s Republic of China and Solomon Islands.\n3939\nHK$29.50\n7D\n-16.2%\n1Y\n282.1%\nEROAD\nMarket Cap: NZ$434.0m\nProvides electronic on-board units and software as a service to the transport industry in New Zealand, the United States, and Australia.\nERD\nNZ$2.32\n7D\n0.4%\n1Y\n78.5%\nSavaria\nMarket Cap: CA$1.5b\nProvides accessibility solutions for the elderly and physically challenged people in Canada, the United States, Europe, and internationally.\nSIS\nCA$21.15\n7D\n0.5%\n1Y\n5.6%\nWix.com\nMarket Cap: US$7.4b\nOperates a cloud-based web development platform for registered users and creators worldwide.\nWIX\nUS$131.82\n7D\n2.4%\n1Y\n-20.6%\nKeePer Technical Laboratory\nMarket Cap: JP\u00a594.0b\nDevelops, manufactures, and sells car coatings, car washing chemicals and equipment, and other products in Japan.\n6036\nJP\u00a53,445.00\n7D\n-1.3%\n1Y\n-7.9%\nNorconsult\nMarket Cap: NOK 14.2b\nProvides consultancy services with focus on community planning, engineering design, and architecture in the Nordics and internationally.\nNORCO\nNOK 45.80\n7D\n6.9%\n1Y\n32.9%\nCosmax\nMarket Cap: \u20a92.4t\nResearches, develops, produces, and manufactures cosmetic and health function food products in Korea and internationally.\nA192820\n\u20a9213,000.00\n7D\n12.0%\n1Y\n75.5%\nMatsuya R&DLtd\nMarket Cap: JP\u00a515.4b\nDevelops, manufactures, and sells stitching systems for automobile safety devices in Japan.\n7317\nJP\u00a5720.00\n7D\n2.1%\n1Y\n9.4%\nCorporativo Fragua. de\nMarket Cap: Mex$51.3b\nOperates pharmacy stores under the Superfarmacia name in Mexico.\nFRAGUA B\nMex$536.00\n7D\n-0.6%\n1Y\n-48.4%\nUWC Berhad\nMarket Cap: RM 3.0b\nAn investment holding company, engages in the provision of precision sheet metal fabrication, precision machined components, and value-added assembly services.\nUWC\nRM 2.71\n7D\n-1.5%\n1Y\n0.7%\nHillgrove Resources\nMarket Cap: AU$96.7m\nEngages in the operation, exploration, and development of mineral properties in Australia.\nHGO\nAU$0.037\n7D\n5.7%\n1Y\n-33.9%\nInvestar Holding\nMarket Cap: US$230.2m\nOperates as the bank holding company for Investar Bank that provides a range of commercial banking products to individuals, professionals, and small to medium-sized businesses in south Louisiana, southeast Texas, and Alabama in the United States.\nISTR\nUS$23.42\n7D\n6.4%\n1Y\n27.8%\nFaraday Technology\nMarket Cap: NT$38.8b\nOperates as a fabless ASIC/SoC and silicon intellectual property (IP) provider in China, Taiwan, Japan, the United States, and internationally.\n3035\nNT$149.00\n7D\n-2.9%\n1Y\n-49.8%\nJiangxi Rimag Group\nMarket Cap: HK$7.0b\nInvests and operates medical imaging centers in China.\n2522\nHK$19.11\n7D\n-18.0%\n1Y\n5.1%\nSolarEdge Technologies\nMarket Cap: US$2.0b\nDesigns, develops, manufactures, and sells direct current (DC) optimized inverter systems for solar photovoltaic (PV) installations in the United States, Germany, the Netherlands, Italy, rest of Europe, and internationally.\nSEDG\nUS$34.30\n7D\n10.1%\n1Y\n31.3%\nATON Green Storage\nMarket Cap: \u20ac15.6m\nEngages in the production and sale of storage systems for photovoltaic systems and battery energy storage system.\nATON\n\u20ac2.08\n7D\n1.0%\n1Y\n-64.4%\nHypera\nMarket Cap: R$15.0b\nOperates as a pharmaceutical company in Brazil.\nHYPE3\nR$23.75\n7D\n4.1%\n1Y\n-23.5%\nReckon\nMarket Cap: AU$68.5m\nProvides software solutions in Australia, New Zealand, the United States, and internationally.\nRKN\nAU$0.60\n7D\n-4.0%\n1Y\n18.6%\nSunjin Beauty ScienceLtd\nMarket Cap: \u20a9128.1b\nSUNJIN BEAUTY SCIENCE Co. ,Ltd. researches, develops, manufactures, and exports cosmetics, surfactant, and polymer bead products.\nA086710\n\u20a910,670.00\n7D\n-4.4%\n1Y\n-3.8%\nPeapack-Gladstone Financial\nMarket Cap: US$498.5m\nOperates as the bank holding company for Peapack Private Bank & Trust that provides private banking and wealth management services in the United States.\nPGC\nUS$28.46\n7D\n7.2%\n1Y\n1.2%\nABO Energy GmbH KGaA\nMarket Cap: \u20ac337.5m\nDevelops renewable energy projects in Germany and internationally.\nAB9\n\u20ac36.60\n7D\n-4.4%\n1Y\n-21.8%\nMetropolitan Bank Holding\nMarket Cap: US$801.6m\nOperates as the bank holding company for Metropolitan Commercial Bank that provides a range of business, commercial, and retail banking products and services.\nMCB\nUS$76.92\n7D\n5.4%\n1Y\n47.6%\nAquila Part Prod Com\nMarket Cap: RON 1.7b\nProvides distribution and logistics services in Romania, Moldova, Poland, the Netherlands, Germany, and internationally.\nAQ\nRON 1.46\n7D\n1.3%\n1Y\n3.8%\nRobit Oyj\nMarket Cap: \u20ac24.4m\nEngages in the design, manufacture, and sale of drilling consumables for mining, quarrying, construction, and well drilling industries in Finland.\nROBIT\n\u20ac1.16\n7D\n-3.3%\n1Y\n-31.4%\nLATAM Airlines Group\nMarket Cap: CL$13.7t\nProvides passenger and cargo air transportation services in Chile, Argentina, Peru, Colombia, Ecuador, Brazil, the United States, other Latin American countries, the Caribbean, Europe, and Oceania.\nLTM\nCL$23.09\n7D\n9.0%\n1Y\n96.2%\nHonkarakenne Oyj\nMarket Cap: \u20ac16.9m\nDesigns, manufactures, and sells log and solid-wood house packages in Finland.\nHONBS\n\u20ac2.87\n7D\n4.0%\n1Y\n-0.3%\nApotea\nMarket Cap: SEK 11.2b\nOperates an online pharmacy in Sweden.\nAPOTEA\nSEK 107.22\n7D\n-4.1%\n1Y\nn/a\nAtea\nMarket Cap: NOK 16.3b\nProvides IT infrastructure and related solutions for businesses and public sector organizations in the Nordic countries and Baltic regions.\nATEA\nNOK 146.20\n7D\n1.2%\n1Y\n1.4%\nSRE Holdings\nMarket Cap: JP\u00a549.4b\nEngages in the AI cloud and consulting, and real estate tech businesses in Japan.\n2980\nJP\u00a53,070.00\n7D\n-5.4%\n1Y\n-33.0%\nCustomers Bancorp\nMarket Cap: US$2.2b\nOperates as the bank holding company for Customers Bank that provides banking products and services.\nCUBI\nUS$68.72\n7D\n4.3%\n1Y\n34.7%\nAustal\nMarket Cap: AU$2.9b\nEngages in the design, manufacture, and support of vessels for commercial and defense customers worldwide.\nASB\nAU$6.81\n7D\n0.7%\n1Y\n204.0%"
    },
    {
      "url": "https://simplywall.st/company/id/6fb23837-8aa9-4491-ae86-533b66bc5506/health?utm_medium=finance_user&utm_campaign=integrated-pitch&utm_source=yahoo&blueprint=4014157",
      "text": "Simcere Pharmaceutical Group Balance Sheet Health\nFinancial Health criteria checks 6/6\nSimcere Pharmaceutical Group has a total shareholder equity of CN\u00a57.2B and total debt of CN\u00a51.1B, which brings its debt-to-equity ratio to 14.6%. Its total assets and total liabilities are CN\u00a512.6B and CN\u00a55.4B respectively. Simcere Pharmaceutical Group's EBIT is CN\u00a51.3B making its interest coverage ratio 23.3. It has cash and short-term investments of CN\u00a52.7B.\nKey information\n14.63%\nDebt to equity ratio\nCN\u00a51.06b\nDebt\n| Interest coverage ratio | 23.3x |\n| Cash | CN\u00a52.68b |\n| Equity | CN\u00a57.23b |\n| Total liabilities | CN\u00a55.37b |\n| Total assets | CN\u00a512.60b |\nRecent financial health updates\nNo updates\nRecent updates\nSimcere Pharmaceutical Group Limited's (HKG:2096) 30% Jump Shows Its Popularity With Investors\nJul 29Simcere Pharmaceutical Group Limited (HKG:2096) Looks Just Right With A 28% Price Jump\nMay 20We Like Simcere Pharmaceutical Group's (HKG:2096) Earnings For More Than Just Statutory Profit\nMay 06Simcere Pharmaceutical Group Limited's (HKG:2096) Price In Tune With Revenues\nMar 06Simcere Pharmaceutical Group Limited's (HKG:2096) P/S Still Appears To Be Reasonable\nNov 21Simcere Pharmaceutical Group Limited (HKG:2096) Not Lagging Market On Growth Or Pricing\nJul 29Why Simcere Pharmaceutical Group's (HKG:2096) Shaky Earnings Are Just The Beginning Of Its Problems\nMay 01Simcere Pharmaceutical Group Limited's (HKG:2096) Business And Shares Still Trailing The Market\nDec 29Need To Know: Analysts Just Made A Substantial Cut To Their Simcere Pharmaceutical Group Limited (HKG:2096) Estimates\nAug 28Are Investors Undervaluing Simcere Pharmaceutical Group Limited (HKG:2096) By 40%?\nJun 03Analysts Just Shaved Their Simcere Pharmaceutical Group Limited (HKG:2096) Forecasts Dramatically\nApr 06Estimating The Intrinsic Value Of Simcere Pharmaceutical Group Limited (HKG:2096)\nJan 10Financial Position Analysis\nShort Term Liabilities: 2096's short term assets (CN\u00a56.1B) exceed its short term liabilities (CN\u00a53.5B).\nLong Term Liabilities: 2096's short term assets (CN\u00a56.1B) exceed its long term liabilities (CN\u00a51.8B).\nDebt to Equity History and Analysis\nDebt Level: 2096 has more cash than its total debt.\nReducing Debt: 2096's debt to equity ratio has reduced from 187.2% to 14.6% over the past 5 years.\nDebt Coverage: 2096's debt is well covered by operating cash flow (131.4%).\nInterest Coverage: 2096's interest payments on its debt are well covered by EBIT (23.3x coverage).\nBalance Sheet\nDiscover healthy companies\nCompany Analysis and Financial Data Status\n| Data | Last Updated (UTC time) |\n|---|---|\n| Company Analysis | 2025/08/24 23:09 |\n| End of Day Share Price | 2025/08/22 00:00 |\n| Earnings | 2025/06/30 |\n| Annual Earnings | 2024/12/31 |\nData Sources\nThe data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.\n| Package | Data | Timeframe | Example US Source * |\n|---|---|---|---|\n| Company Financials | 10 years |\n| |\n| Analyst Consensus Estimates | +3 years |\n|\n|\n| Market Prices | 30 years |\n| |\n| Ownership | 10 years |\n| |\n| Management | 10 years |\n| |\n| Key Developments | 10 years |\n|\n* Example for US securities, for non-US equivalent regulatory forms and sources are used.\nUnless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.\nAnalysis Model and Snowflake\nDetails of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.\nLearn about the world class team who designed and built the Simply Wall St analysis model.\nIndustry and Sector Metrics\nOur industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.\nAnalyst Sources\nSimcere Pharmaceutical Group Limited is covered by 17 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.\n| Analyst | Institution |\n|---|---|\n| Shaojing Tong | BofA Global Research |\n| Bo Yu | China International Capital Corporation Limited |\n| Shitong Han | Citic Securities Co., Ltd. |"
    },
    {
      "url": "https://simplywall.st/company/id/664ac572-b488-49cf-99f5-750a89324d62?utm_medium=finance_user&utm_campaign=cta&utm_source=yahoo&blueprint=4014157",
      "text": "Chugai Pharmaceutical (4519) Stock Overview\nEngages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. More details\n| Snowflake Score | |\n|---|---|\n| Valuation | 4/6 |\n| Future Growth | 4/6 |\n| Past Performance | 3/6 |\n| Financial Health | 6/6 |\n| Dividends | 3/6 |\n4519 Community Fair Values\nSee what others think this stock is worth. Follow their fair value or set your own to get alerts.\nChugai Pharmaceutical Co., Ltd. Competitors\nPrice History & Performance\n| Historical stock prices | |\n|---|---|\n| Current Share Price | JP\u00a56,270.00 |\n| 52 Week High | JP\u00a58,655.00 |\n| 52 Week Low | JP\u00a55,942.00 |\n| Beta | 0.69 |\n| 1 Month Change | -14.59% |\n| 3 Month Change | -17.09% |\n| 1 Year Change | -13.16% |\n| 3 Year Change | 69.23% |\n| 5 Year Change | 34.18% |\n| Change since IPO | 1,392.86% |\nRecent News & Updates\nChugai Pharmaceutical Co., Ltd.'s (TSE:4519) Shareholders Might Be Looking For Exit\nAug 17Chugai Pharmaceutical Co., Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now\nJul 26If EPS Growth Is Important To You, Chugai Pharmaceutical (TSE:4519) Presents An Opportunity\nJul 10Recent updates\nChugai Pharmaceutical Co., Ltd.'s (TSE:4519) Shareholders Might Be Looking For Exit\nAug 17Chugai Pharmaceutical Co., Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now\nJul 26If EPS Growth Is Important To You, Chugai Pharmaceutical (TSE:4519) Presents An Opportunity\nJul 10Chugai Pharmaceutical's (TSE:4519) Upcoming Dividend Will Be Larger Than Last Year's\nJun 10Chugai Pharmaceutical (TSE:4519) Is Paying Out A Larger Dividend Than Last Year\nMay 21Chugai Pharmaceutical Co., Ltd. Just Recorded A 19% EPS Beat: Here's What Analysts Are Forecasting Next\nApr 27Chugai Pharmaceutical Co., Ltd.'s (TSE:4519) Business Is Yet to Catch Up With Its Share Price\nApr 25Calculating The Intrinsic Value Of Chugai Pharmaceutical Co., Ltd. (TSE:4519)\nMar 17Accelerating RED Capabilities And Robust Pipeline Will Enhance Future Prospects\nEmphasis on RED capabilities and innovative products aims to drive revenue growth and improve net and operating margins.Chugai Pharmaceutical Co., Ltd. (TSE:4519) Just Released Its Yearly Results And Analysts Are Updating Their Estimates\nFeb 03Chugai Pharmaceutical Co., Ltd.'s (TSE:4519) Share Price Could Signal Some Risk\nDec 23Calculating The Fair Value Of Chugai Pharmaceutical Co., Ltd. (TSE:4519)\nDec 05Chugai Pharmaceutical's (TSE:4519) Dividend Will Be \u00a541.00\nOct 30Chugai Pharmaceutical Co., Ltd. Just Beat Revenue By 12%: Here's What Analysts Think Will Happen Next\nOct 29Chugai Pharmaceutical's (TSE:4519) Dividend Will Be \u00a541.00\nOct 15Should You Be Adding Chugai Pharmaceutical (TSE:4519) To Your Watchlist Today?\nOct 12Chugai Pharmaceutical's (TSE:4519) Dividend Will Be \u00a541.00\nSep 24Shareholder Returns\n| 4519 | JP Pharmaceuticals | JP Market | |\n|---|---|---|---|\n| 7D | 0.4% | 1.2% | -0.07% |\n| 1Y | -13.2% | -13.6% | 15.3% |\nReturn vs Industry: 4519 matched the JP Pharmaceuticals industry which returned -13.6% over the past year.\nReturn vs Market: 4519 underperformed the JP Market which returned 15.3% over the past year.\nPrice Volatility\n| 4519 volatility | |\n|---|---|\n| 4519 Average Weekly Movement | 6.3% |\n| Pharmaceuticals Industry Average Movement | 3.8% |\n| Market Average Movement | 3.3% |\n| 10% most volatile stocks in JP Market | 7.5% |\n| 10% least volatile stocks in JP Market | 1.7% |\nStable Share Price: 4519's share price has been volatile over the past 3 months compared to the JP market.\nVolatility Over Time: 4519's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of JP stocks.\nAbout the Company\n| Founded | Employees | CEO | Website |\n|---|---|---|---|\n| 1925 | 5,026 | Osamu Okuda | www.chugai-pharm.co.jp |\nChugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Perjeta, Polivy, Tecentriq, and Phesgo; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi for spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Ronapreve, an anti-SARS-CoV-2 monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has strategic alliances and collaboration with Roche Group; research collaboration and option to license agreement with Araris Biotech AG to develop ADCs using Araris AraLinQ technology; and research and license agreement with Gero PTE.\nChugai Pharmaceutical Co., Ltd. Fundamentals Summary\n| 4519 fundamental statistics | |\n|---|---|\n| Market cap | JP\u00a510.32t |\n| Earnings (TTM) | JP\u00a5395.44b |\n| Revenue (TTM) | JP\u00a51.20t |\nIs 4519 overvalued?\nSee Fair Value and valuation analysisEarnings & Revenue\n| 4519 income statement (TTM) | |\n|---|---|\n| Revenue | JP\u00a51.20t |\n| Cost of Revenue | JP\u00a5354.41b |\n| Gross Profit | JP\u00a5841.80b |\n| Other Expenses | JP\u00a5446.36b |\n| Earnings | JP\u00a5395.44b |\nLast Reported Earnings\nJun 30, 2025\nNext Earnings Date\nOct 24, 2025\n| Earnings per share (EPS) | 240.29 |\n| Gross Margin | 70.37% |\n| Net Profit Margin | 33.06% |\n| Debt/Equity Ratio | 0% |\nHow did 4519 perform over the long term?\nSee historical performance and comparisonDividends\nDoes 4519 pay a reliable dividends?\nSee 4519 dividend history and benchmarks| Chugai Pharmaceutical dividend dates | |\n|---|---|\n| Ex Dividend Date | Jun 27 2025 |\n| Dividend Pay Date | Aug 28 2025 |\n| Days until Ex dividend | 59 days |\n| Days until Dividend pay date | 3 days |\nDoes 4519 pay a reliable dividends?\nSee 4519 dividend history and benchmarksCompany Analysis and Financial Data Status\n| Data | Last Updated (UTC time) |\n|---|---|\n| Company Analysis | 2025/08/24 05:06 |\n| End of Day Share Price | 2025/08/22 00:00 |\n| Earnings | 2025/06/30 |\n| Annual Earnings | 2024/12/31 |\nData Sources\nThe data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.\n| Package | Data | Timeframe | Example US Source * |\n|---|---|---|---|\n| Company Financials | 10 years |\n| |\n| Analyst Consensus Estimates | +3 years |\n|\n|\n| Market Prices | 30 years |\n| |\n| Ownership | 10 years |\n| |\n| Management | 10 years |\n| |\n| Key Developments | 10 years |\n|\n* Example for US securities, for non-US equivalent regulatory forms and sources are used.\nUnless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.\nAnalysis Model and Snowflake\nDetails of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.\nLearn about the world class team who designed and built the Simply Wall St analysis model.\nIndustry and Sector Metrics\nOur industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.\nAnalyst Sources\nChugai Pharmaceutical Co., Ltd. is covered by 27 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.\n| Analyst | Institution |\n|---|---|\n| Atsushi Seki | Barclays |\n| Koichi Mamegano | BofA Global Research |\n| Siti Bte Salikin | CFRA Equity Research |"
    }
  ],
  "argos_summary": "Asian investors are targeting undervalued stocks amid global rate\u2011cut speculation, with Simcere Pharmaceutical Group (2096) highlighted as a strong cash\u2011flow generator trading below its HK$19.08 fair value at HK$14.10 and showing robust earnings growth and a healthy balance sheet.  The company\u2019s 24% projected earnings growth and low debt\u2011to\u2011equity ratio make it an attractive value play.  In contrast, Japan\u2019s Chugai Pharmaceutical (4519) trades at a higher valuation, yet it maintains solid profitability, a strong dividend program, and a diversified oncology pipeline, offering a more growth\u2011oriented but pricier option for investors.",
  "argos_id": "0NORTUWM1"
}